scholarly journals Fibromyalgia-Like Syndrome Associated with Parkinson’s Disease—A Cohort Study

2019 ◽  
Vol 8 (8) ◽  
pp. 1118
Author(s):  
Ran Abuhasira ◽  
Yair Zlotnik ◽  
Anat Horev ◽  
Gal Ifergane
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cohort Study ◽  
Medical Records ◽  
Population Based ◽  
Treatment Resistant ◽  
Distinct Subgroup ◽  
Prevalence Of Depression ◽  
The Mean ◽  
Epidemiological Characteristics

Parkinson’s disease (PD) and fibromyalgia (FM) are two relatively common disorders that are considered distinct diagnoses. The aim of this study was to investigate the epidemiological characteristics of patients with both PD and FM, as well as their comorbidities and medication use. We performed a population-based retrospective cohort study in Israel from 2000 to 2015. We identified patients with PD according to a refined medication tracer algorithm and patients with FM according to their medical records. Using the algorithm, we identified 2606 patients diagnosed with PD, 60 of them (2.3%) were also diagnosed with FM. Most of the patients were females (88.3%) and the mean age of FM diagnosis was 63.95 ± 12.27 years. These patients had a higher prevalence of depression, anxiety, and dementia. Of the patients diagnosed with PD + FM, 46 (76.7%) were diagnosed with FM after the diagnosis of PD. Patients with PD + FM used analgesics of distinct kinds in higher rates, as well as more anti-PD medications. We suggest that patients with PD + FM represent a distinct subgroup with a fibromyalgia-like syndrome associated with Parkinson’s disease (FLISPAD). Their PD is more treatment resistant, and they take more medications, both analgesics and anti-PD.

scholarly journals End-Of-Life Discussions Reduce The Utilization of Life-Sustaining Treatments During The Last Three Months of Life in Cancer Patients : A Nationwide Population-Based Cohort Study

2021 ◽  
Author(s):  
Shang-Yih Chan ◽  
Yun-Ju Lai ◽  
Yu-Yen Hsin Chen ◽  
Shuo-Ju Chiang ◽  
Yi-Fan Tsai ◽  
...  
Keyword(s):  
Cohort Study ◽  
Cardiopulmonary Resuscitation ◽  
End Of Life ◽  
Cancer Patients ◽  
Medical Records ◽  
Population Based ◽  
Lower Likelihood ◽  
The Mean ◽  
The Impact ◽  
To Receive

Abstract Purpose Studies to examine the impact of end-of-life (EOL) discussions on the utilization of life-sustaining treatments near death were limited and had inconsistent findings. This nationwide population-based cohort study determined the impact of EOL discussions on the utilization of life-sustaining treatments in the last three months of life in Taiwanese cancer patients. Methods This cohort study included adult cancer patients from 2012–2018, which were confirmed by pathohistological reports. Life-sustaining treatments during the last three months of life included cardiopulmonary resuscitation, intubation, and defibrillation. EOL discussions in cancer patients were confirmed by their medical records. Association of EOL discussions with utilization of life-sustaining treatments were assessed using multiple logistic regression. Results Of 381,207 patients, the mean age was 70.5 years and 19.4% of the subjects utilized life-sustaining treatments during the last three months of life. After adjusting for other covariates, those who underwent EOL discussions were less likely to receive life-sustaining treatments during the last three months of life compared to those who did not (Adjusted odds ratio [AOR]: 0.82; 95% confidence interval [CI]: 0.80–0.84). Considering the type of treatments, EOL discussions correlated with a lower likelihood of receiving cardiopulmonary resuscitation (AOR = 0.43, 95% CI: 0.41–0.45), endotracheal intubation (AOR = 0.87, 95%CI: 0.85–0.89), and defibrillation (AOR = 0.52, 95%CI: 0.48–0.57). Conclusion EOL discussions correlated with a lower utilization of life-sustaining treatments during the last three months of life among cancer patients. Our study supports the importance of providing these discussions to cancer patients to better align care with preferences during the EOL treatment.

Parkinson’s disease and skin cancer risk: a nationwide population‐based cohort study in Korea

2020 ◽  
Vol 34 (12) ◽  
pp. 2775-2780 ◽  
Author(s):  
H.J. Ryu ◽  
J.‐H. Park ◽  
M. Choi ◽  
J.‐H. Jung ◽  
K. Han ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cohort Study ◽  
Skin Cancer ◽  
Cancer Risk ◽  
Population Based ◽  
Skin Cancer Risk

scholarly journals Tinnitus and risk of Alzheimer’s and Parkinson’s disease: a retrospective nationwide population-based cohort study

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Hsuan-Te Chu ◽  
Chih‐Sung Liang ◽  
Ta-Chuan Yeh ◽  
Li-Yu Hu ◽  
Albert C. Yang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cohort Study ◽  
Population Based

scholarly journals Tonsillectomy and risk of Parkinson's disease: A danish nationwide population-based cohort study

2017 ◽  
Vol 33 (2) ◽  
pp. 321-324 ◽  
Author(s):  
Elisabeth Svensson ◽  
Victor W. Henderson ◽  
Szimonetta Szépligeti ◽  
Morten Gersel Stokholm ◽  
Tejs Ehlers Klug ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cohort Study ◽  
Population Based

P3-055: Incidence of dementia in elderly Parkinson's disease: A 15-year population-based cohort study

2010 ◽  
Vol 6 ◽  
pp. S465-S465
Author(s):  
François Tison ◽  
Catherine Helmer ◽  
Florian Perez ◽  
Sophie Auriacombe ◽  
Jean-François Dartigues
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cohort Study ◽  
Population Based ◽  
Incidence Of Dementia

scholarly journals Risk of dementia and Parkinson’s disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study

PLoS ONE ◽  
2020 ◽  
Vol 15 (12) ◽  
pp. e0244660
Author(s):  
Myungsun Shim ◽  
Woo Jin Bang ◽  
Cheol Young Oh ◽  
Yong Seong Lee ◽  
Seong Soo Jeon ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cohort Study ◽  
Propensity Score ◽  
Androgen Deprivation Therapy ◽  
Validation Cohort ◽  
Population Based ◽  
Gonadotropin Releasing Hormone ◽  
Gonadotropin Releasing Hormone Agonist

Recent studies reported conflicting results on the association of androgen deprivation therapy (ADT) with dementia and Parkinson’s disease in patients with prostate cancer (Pca). Therefore, this study aimed to investigate whether use of gonadotropin-releasing hormone agonist (GnRHa) increases the risk of both diseases. A nationwide population cohort study was conducted involving newly diagnosed patients with Pca %who started ADT with GnRHa (GnRHa users, n = 3,201) and control (nonusers, n = 4,123) between January 1, 2012, and December 31, 2016, using data from the National Health Insurance Service. To validate the result, a hospital cohort of patients with Pca consisting of GnRHa users (n = 205) and nonusers (n = 479) in a tertiary referral center from January 1, 2006 to December 31, 2016, were also analyzed. Traditional and propensity score-matched Cox proportional hazards models were used to estimate the effects of ADT on the risk of dementia and Parkinson’s disease. In univariable analysis, risk of dementia was associated with GnRHa use in both nationwide and hospital validation cohort (hazard ratio [HR], 1.696; 95% CI, 1.425–2.019, and HR, 1.352; 95% CI, 1.089–1.987, respectively). In a nationwide cohort, ADT was not associated with dementia in both traditional and propensity score-matched multivariable analysis, whereas in a hospital validation cohort, ADT was associated with dementia only in unmatched analysis (HR, 1.203; 95% CI, 1.021–1.859) but not in propensity score-matched analysis. ADT was not associated with Parkinson’s disease in either nationwide and validation cohorts. This population-based study suggests that the association between GnRHa use as ADT and increased risk of dementia or Parkinson’s disease is not clear, which was also verified in a hospital validation cohort.

Sign in / Sign up

Export Citation Format

Share Document